Measurement of Serum Survivin to Discriminate Patients with Breast Cancer from Normal Subjects

Background and Aims: There is now an increasing body of evidence that survivin is a protein, expressed highly in breast cancer. The signaling interaction of protein survivin in breast cancer is still unclear, but physiological regulation of survivin seems to be linked to the breast cancer occurrence and severity of it. Materials and Methods: Serum samples were obtained from April 2015 to November 2017 out of women enrolled in a group undergoing annual breast cancer testing. Routine blood samples were analyzed at the Biochemical Laboratory of Rouhani Babol University Hospital . Results: Serum levels of survivin in patients with breast cancer group increased compared to the healthy controls [207.520 ±110.284 (mean ±SD) vs. 126.212 ±53.130, ng/L, p 0.001]. Also, we detected a positive correlation between elevated serum survivin level and clinical characteristics of patients with breast cancer. Conclusions: Serum survivin measurement was shown to discriminate patients with breast cancer from healthy controls. However, further studies are needed to confirm this role and its benefits.